2025-04-08 18:17:58
Latest Post
Godrej Properties delivers its highest ever quarterly and full year bookings
Poonawalla Fincorp Launches Shopkeeper Loan Business
Revolt Motors Expands to 200 Dealerships, Targets 400 by FY26
Sobha Ltd - Real Estate Operational Update - Q4 FY 2024-25
Lemon Tree Hotels signs a new property in DarjeelingStock Report
Syngene International Ltd Q1FY22 consolidated PAT slides QoQ to Rs. 77.3 crore
Posted On : 2021-07-20 22:21:49( TIMEZONE : IST )
Syngene International Ltd has reported financial results for the period ended June 30, 2021.
Financial Results (Q1 FY 2021-22) - QoQ Comparison
The company has reported total income of Rs.606.8 crores during the period ended June 30, 2021 as compared to Rs.677 crores during the period ended March 31, 2021.
The company has posted net profit / (loss) of Rs.77.3 crores for the period ended June 30, 2021 as against net profit / (loss) of Rs.160.6 crores for the period ended March 31, 2021.
The company has reported EPS of Rs.1.89 for the period ended June 30, 2021 as compared to Rs.4.01 for the period ended March 31, 2021.
| Financials | Q1 FY2021-22 | Q4 FY20-21 | % Change |
| Total Income | ₹ 606.8 crs | ₹ 677 crs |  -10.37% |
| Net Profit | ₹ 77.3 crs | ₹ 160.6 crs | -51.87% |
| EPS | ₹ 1.89 | ₹ 4.01 | -52.87% |
Financial Results (Q1 FY 2021-22) - YoY Comparison
The company has reported total income of Rs.606.8 crores during the period ended June 30, 2021 as compared to Rs.436.9 crores during the period ended June 30, 2020.
The company has posted net profit / (loss) of Rs.77.3 crores for the period ended June 30, 2021 as against net profit / (loss) of Rs.58 crores for the period ended June 30, 2020.
The company has reported EPS of Rs.1.89 for the period ended June 30, 2021 as compared to Rs.1.46 for the period ended June 30, 2020.
| Financials | Q1 FY2021-22 | Q1 FY2020-21 | % Change |
| Total Income | ₹ 606.8 crs | ₹ 436.9 crs |  38.89% |
| Net Profit | ₹ 77.3 crs | ₹ 58 crs | 33.28% |
| EPS | ₹ 1.89 | ₹ 1.46 | 29.45% |
Commenting on the results, Jonathan Hunt, Managing Director and Chief Executive Officer, Syngene International Limited, said, "We made a strong start to the financial year. Besides continuing progress across all our business divisions, growth for the quarter was strongly boosted by the manufacturing of COVID-19 treatment, Remdesivir, as we increased production to meet the needs of the second wave of COVID-19 in India. We also made headway with the expansion of our dedicated R&D center for Bristol Myers Squibb following the contract extension announced last quarter.
As India faced a second wave of the pandemic, our safety protocols continued to provide a sustainable work environment enabling our staff to operate at normal levels and keep client projects on track. During the quarter, following government guidance, we were proud to be able to offer vaccinations to our staff and their families as an additional level of protection.
Overall, first quarter performance was in line with our expectations and puts us on track to meet our full year growth guidance in the coming quarters."
Shares of Syngene International Ltd was last trading in BSE at Rs. 652.8 as compared to the previous close of Rs. 669.1. The total number of shares traded during the day was 85395 in over 3868 trades.
The stock hit an intraday high of Rs. 687.5 and intraday low of 647.05. The net turnover during the day was Rs. 56813755.
